Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Thymosin alpha1 for Severe Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe sepsis according to ACCP/CCM criteria~* Patient or legally authorized representative able to provide informed consent~Exclusion Criteria:~* Subject is less than 18 years or more than 85 years of age~* If female, the subject is pregnant or nursing~* Subject is receiving immunosuppressive therapy such as cyclosporine, azothioprine,or cancer-related chemotherapy~* Patient not expected to survive 28 days because of uncorrectable medical condition, such as poorly controlled neoplasm or other end-stage disease~* History of bone marrow, lung, liver, pancreas, or small-bowel transplantation~* Acute pancreatitis with no established source of infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin alpha 1+Standard Therapy (Type: EXPERIMENTAL): Patients receive treatment based on SSC guideline with additional thymosin alpha1
- normal saline+standard therapy (Type: PLACEBO_COMPARATOR): Patients receive treatment based on SSC guideline with additional normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).